February means not only Valentine's Day but heart health awareness month for women. Our curated selection of hot red gear and ...

Getty Images Pharmaceutical company Eli Lilly is expected to report fourth-quarter earnings before the bell Thursday. Analysts tracking the company see increased sales and profit for Eli Lilly in ...

President Donald Trump scored a significant legal win Monday in his lawsuit against the members of the Pulitzer Prize Board, paving the way towards the discovery phase in their courtroom battle.

Eli Lilly's stock price finished Jan. 16 down 21% from a peak it set last September. The sales trajectory of Mounjaro and Zepbound tapered off in the second half of 2024. An oral weight-loss ...

“You Need to Calm Down,” because POPFLEX has just dropped Taylor Swift’s favorite skort in a new color. POPFLEX added a new shade — Royal Orchid — to the already expansive Pirouette ...

Boris Becker's ex-wife Lilly has won the German version of I'm A Celebrity... Get Me Out Of Here! after stealing the hearts of the nation. The former Wimbledon tennis star, 57, has endured a ...

Eli Lilly, the world’s biggest drugmaker by market value, reported higher-than-expected quarterly profit and issued a bullish earnings forecast. Sales of weight-loss drug Zepbound and diabetes ...

Eli Lilly and Company (NYSE:LLY) will increase its dividend from last year's comparable payment on the 10th of March to $1.50. This takes the annual payment to 0.8% of the current stock price ...

Bell’s career as a cartoonist spans decades, earning him significant accolades, including the 2019 Pulitzer Prize for editorial cartoons. His award-winning work, praised for tackling issues such ...

In this article, we are going to take a look at where Eli Lilly And Co. (NYSE:LLY) stands against other stocks that could split in the near future. Stock splits don’t change how much a company ...

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the drugmaker came out with a mostly better-than-expected 2025 forecast.

It is the largest study ever of the drug category—which includes Novo Nordisk’s GLP-1 treatments Ozempic and Wegovy and Eli Lilly’s dual-action GLP-1/GIP agonists Mounjaro and Zepbound.